The Spanish biosimilars industry is experiencing a reduction of prices, regulatory changes regarding product approval, and increased local and global competition, which is a complex topic…
In Conversation
... we excel in supply chain, keeping in mind that our model is B2B; our success relies on delivering products on time so that clients can…
I am a great believer in the US system and feel that there is a lot of misinformation about it.
The technical and economic advantage of using zebrafish is due to the ability to study multiple organisms in a reduced space.
... in Italy we have developed a dual strategy: on one side in-licence local generic products; while on the other side ... increase our business development…
... Germany and the UK are the next strategic targets, but in those markets we will focus first on innovation.
... Andalusia’s hospitals have never been fully saturated throughout the entire pandemic, which has allowed us to be supportive of other regions, sending ventilators and receiving…
Italy has a key role to play in the EU objective of guaranteeing continuity of supply during emergencies.
My dream is that Italy, thanks to its infrastructure and location, can become the leading pharma manufacturing logistics hub for the Mediterranean region, joining northern Africa…
The first approval of a regenerative medicine product in Korea was in 2002. Since then, a total of 15 cell and gene therapies, including immunotherapies and…
While Organon’s portfolio is meeting the needs of women, it is not enough. Governments and policymakers realise that they need to have tangible projects and approaches…
Accord recognises biosimilars as a future growth driver for the company. It is common sense as medicine moves to biologics and biologics move toward gene and…
